GeneTherapyLive’s Weekly Rewind – February 11, 2022

Article

Review top news and interview highlights from the week ending February 11, 2022.

Welcome to GeneTherapyLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Assessing EtranaDez for Hemophilia B in HOPE-B: Wolfgang Miesbach, MD, PhD

The professor and head of coagulation disorders and Comprehensive Care Centre, University Hospital of Frankfurt, Germany, discussed results of the final analysis of the HOPE-B study. He gave an overview of the study, discussing the positive data and outcomes.

2. Stargardt Disease Gene Therapy IND Cleared to Proceed

Nanoscope Therapeutics has received approval from the FDA for its investigational new drug application for MCO-010, a gene therapy for the potential treatment of Stargardt disease, a type of macular degeneration.

3. The Importance of Collaboration in Developing Next Generation Cell Therapies

Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed the company’s collaboration with 2seventy bio to develop TCR T-cell therapies as well as future collaborations and research that Medigene is pursuing.

4. CAR T-Cell Therapy Efficacious at 10 Years in Chronic Lymphocytic Leukemia

New findings, from a recent study evaluating 10-year follow-up of patients with complete responses to chronic lymphocytic leukemia (CLL) chimeric antigen receptor (CAR) T-cell treatment, have elucidated the long-term role of CD19+ CAR T-cells in the body.

5. Treating Solid Tumors With Personalized Immunotherapy: Julian Molina, MD, PhD

The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors and developing personalized immunotherapies for solid tumors.

Recent Videos
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.